| |
Cost (US$)
|
QALYs or LYs
|
ICER (US$)
|
Probability of cost-effectiveness, dapagliflozin vs. standard care (%)
|
|---|
| |
Add-on dapagliflozin
|
Standard care
|
\(\Delta\) Costs
|
Add-on dapagliflozin
|
Standard care
|
\(\Delta\) QALYs or \(\Delta \mathrm{LYs}\)
| |
WTP at US$ 25,000
|
WTP at US$ 75,000
|
|---|
|
Base-case analysis
| | | | | | | | | |
|
QALY gain as effectiveness outcome
|
87,805
|
76,501
|
11,304
|
11.03
|
10.09
|
0.94
|
12,035
|
99.3
|
100
|
|
LY gain as effectiveness outcome
|
87,805
|
76,501
|
11,304
|
14.71
|
13.46
|
1.25
|
9,080
|
100
|
100
|
|
Scenario analyses
| |
|
(1) Time horizon
| | | | | | | | | |
|
30 years
|
104,623
|
87,940
|
16,682
|
13.14
|
11.60
|
1.54
|
10,832
|
100
|
100
|
|
18 months
|
16,719
|
15,732
|
987
|
2.10
|
2.08
|
0.03
|
37,386
|
43.8
|
61.8
|
|
(2) Discounting rate
| | | | | | | | | |
|
0%
|
104,288
|
90,112
|
14,176
|
13.1
|
11.89
|
1.21
|
11,681
|
100
|
100
|
|
10%
|
62,215
|
55,130
|
7,085
|
7.82
|
7.27
|
0.54
|
13,007
|
97.3
|
100
|
|
(3) Under assumption of equal risk of clinical events between the two treatments
|
|
Cardiovascular death
|
81,581
|
76,501
|
5,081
|
10.20
|
10.09
|
0.11
|
44,670
|
33
|
60.9
|
|
Non-cardiovascular death
|
86,887
|
76,501
|
10,387
|
10.91
|
10.9
|
0.82
|
12,704
|
98.9
|
100
|
|
Hospitalization for HF
|
87,995
|
76,501
|
11,444
|
11.03
|
10.09
|
0.94
|
12,204
|
99.6
|
100
|
|
Emergency visits for HF
|
87,818
|
76,501
|
11,317
|
11.03
|
10.09
|
0.94
|
12,055
|
99.9
|
100
|
|
(4) Adverse events of treatments considered in the model
|
88,074
|
76,727
|
11,347
|
10.95
|
10.02
|
0.92
|
12,288
|
99.3%
|
100
|
- QALY quality-adjusted life-year, ICER incremental cost-effectiveness ratio, WTP willingness-to-pay, LY life-year, HF heart failure
